Urology, Baoding No 1 Central Hospital, Baoding, Hebei, China
Prostate & Andrology Key Laboratory of Baoding, Baoding, Hebei, China.
BMJ Open. 2023 Oct 29;13(10):e074455. doi: 10.1136/bmjopen-2023-074455.
Enhanced recovery after surgery is widely used in the perioperative period in the field of urology; however, it lacks comprehensive and systematic evidence supporting its efficacy and safety after percutaneous nephrolithotomy. This meta-analysis aimed to assess the safety and efficacy of enhanced recovery after percutaneous nephrolithotomy.
Relevant databases, including PubMed, Web of Science, Embase, The Cochrane Library, China Knowledge Resource Integrated Database, Wanfang Database, Chinese Biomedical Document Service System, and Chinese Science and Technology Journal Database, will be searched from their inception to 19 September 2022. Two researchers will independently screen the literature, extract data and evaluate the included studies. The Grading of Recommendations, Assessment, Development, and Evaluation will be used to assess the degree of certainty of the evidence. Based on the Cochrane Handbook V.5.1.0, the risk of bias assessment of the included randomised controlled trials will be assessed. Based on their randomisation method, allocation generation, concealment, blinding and follow-up, we will assess randomised controlled trials. Random-effects and fixed-effects models and subgroup analyses will be used for meta-analysis. RevMan V.5.4.1 will be used for data collection and meta-analysis.
Due to the nature of this systematic review, ethics approval is not required for this study. We will publish the results of this review in a peer-reviewed journal.
CRD42023411520.
加速康复外科在泌尿外科围手术期得到广泛应用,但经皮肾镜取石术后缺乏全面系统的证据支持其疗效和安全性。本荟萃分析旨在评估经皮肾镜取石术后加速康复的安全性和有效性。
我们将从建库至 2022 年 9 月 19 日检索相关数据库,包括 PubMed、Web of Science、Embase、The Cochrane Library、中国知识资源总库、万方数据库、中国生物医学文献服务系统和中文科技期刊数据库。两名研究者将独立筛选文献、提取数据和评估纳入研究。我们将使用推荐、评估、发展和评估分级(Grading of Recommendations, Assessment, Development, and Evaluation)来评估证据的确定性程度。根据 Cochrane 手册 V.5.1.0,我们将评估纳入的随机对照试验的偏倚风险。我们将根据其随机化方法、分配生成、隐藏、盲法和随访情况,对随机对照试验进行评估。我们将使用随机效应和固定效应模型以及亚组分析进行荟萃分析。RevMan V.5.4.1 将用于数据收集和荟萃分析。
由于本系统评价的性质,本研究不需要伦理批准。我们将在同行评议的期刊上发表本综述的结果。
PROSPERO 注册号:CRD42023411520。